Related Experiment Video
Updated: May 27, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis
Corinna Trebst1, Paul Bronzlik, Jan T Kielstein
1Department of Neurology, Hannover Medical School, Hannover, Germany. trebst.corinna @ mh-hannover.de
Blood Purification
|November 17, 2011
Summary
Immunoadsorption (IA) effectively treats steroid-unresponsive multiple sclerosis (MS) relapses, showing good tolerance. This approach offers a promising alternative for MS patients experiencing relapses unresponsive to steroids.
Area of Science:
- Neurology
- Immunology
- Therapeutics
Background:
- Therapeutic plasma exchange (TPE) is established for steroid-unresponsive multiple sclerosis (MS) relapses, with up to 70% response rates.
- Immunoadsorption (IA) selectively removes immunoglobulins, offering a potential alternative to TPE for MS relapses.
- Limited data exists on IA therapy for steroid-unresponsive MS relapses.
Purpose of the Study:
- To evaluate the efficacy and tolerability of IA therapy in patients with steroid-unresponsive MS relapses.
- To compare IA therapy with established treatments like TPE for MS relapses.
Main Methods:
- A case series of 10 patients with steroid-unresponsive MS relapses treated with IA therapy.
- Clinical response and tolerability were assessed post-treatment.
Main Results:
- 66% of patients experienced marked to moderate clinical improvement with clear functional gain.
- IA therapy was well-tolerated by the studied patients.
Conclusions:
- IA therapy represents an effective and well-tolerated treatment option for steroid-unresponsive MS relapses.
- IA may be a viable alternative to TPE for managing difficult MS relapses.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...